Get the Stockscreener App
1.28
1.54%
-0.02
After Hours:
1.27
-0.01
-0.78%
Hoth Therapeutics Inc stock is traded at $1.28, with a volume of 75,301.
It is down -1.54% in the last 24 hours and up +7.56% over the past month.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
See More
Previous Close:
$1.30
Open:
$1.3
24h Volume:
75,301
Relative Volume:
0.07
Market Cap:
$16.91M
Revenue:
-
Net Income/Loss:
$-7.51M
P/E Ratio:
-0.9697
EPS:
-1.32
Net Cash Flow:
$-8.02M
1W Performance:
+2.40%
1M Performance:
+7.56%
6M Performance:
-5.88%
1Y Performance:
+58.02%
1-Day Range:
$1.28
$1.3198
1-Week Range:
$1.2333
$1.38
52-Week Range:
$0.58
$3.80
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Name
Hoth Therapeutics Inc
Sector
Industry
Phone
(646)756-2997
Address
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Compare HOTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
1.28 | 17.17M | 0 | -7.51M | -8.02M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-19 | Initiated | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Stock (HOTH) Latest News
What analysts say about Hoth Therapeutics Inc. stockFree Wealth Management Insights - Autocar Professional
What drives Hoth Therapeutics Inc. stock priceFree Trading Strategy Suggestions - Autocar Professional
Hoth Therapeutics Inc. Stock Analysis and ForecastHigh-yield trading alerts - Autocar Professional
Is Hoth Therapeutics Inc. a good long term investmentLightning-fast capital gains - jammulinksnews.com
Hoth Therapeutics shares fall 1.52% intraday after signing VA research deal to advance GDNF as breakthrough therapy for obesity and fatty liver. - AInvest
Hoth Therapeutics partners with VA to test GDNF therapy for obesity By Investing.com - Investing.com South Africa
Hoth Therapeutics partners with VA to test GDNF therapy for obesity - Investing.com Australia
New Weight Loss Drug Challenger GDNF Takes On Semaglutide in Landmark VA Obesity Study - Stock Titan
Why Hoth Therapeutics Inc. stock attracts strong analyst attentionElite Investor Club - Newser
How Hoth Therapeutics Inc. stock performs during market volatilitySwing Trade Signals - Newser
What makes Hoth Therapeutics Inc. stock price move sharplyDaily Volume Leaders - Newser
Hoth Therapeutics (NASDAQ:HOTH) Upgraded by Wall Street Zen to Hold Rating - Defense World
Traumatic Brain Injury Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market | Daily Courier - FinancialContent
Hoth Therapeutics Advances HT-001 for Cancer Treatment - TipRanks
HT-001's Breakthrough in Oncology Supportive Care: A Game-Changer for Hoth Therapeutics? - AInvest
Hoth Therapeutics stock rises after positive Phase 2a trial results By Investing.com - Investing.com UK
Leading Cancer Experts Reveal Phase 2 Data for Revolutionary Skin Toxicity Treatment HT-001 - Stock Titan
Hoth Therapeutics Regains Nasdaq Compliance on June 18 - TipRanks
Hoth Therapeutics reports positive preclinical safety data for HT-KIT By Investing.com - Investing.com South Africa
Hoth Therapeutics Regains Nasdaq Compliance - MarketScreener
Hoth Therapeutics regains Nasdaq compliance after meeting minimum bid - Investing.com
Hoth Therapeutics Just Cleared Critical Nasdaq Hurdle: What This Means for Its $1B+ Biotech Pipeline - Stock Titan
Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT Dose-Dependent Liver Activity with No Observed Toxicity Supports Ind Pathway - MarketScreener
Hoth Therapeutics reports positive preclinical safety data for HT-KIT - Investing.com
Hoth Therapeutics (HOTH) Reports Promising Preclinical Outcomes for Cancer Drug | HOTH Stock News - GuruFocus
Cancer Drug Breakthrough: Hoth's HT-KIT Achieves Perfect Safety Profile Ahead of Clinical Trials - Stock Titan
Hoth Therapeutics regains Nasdaq compliance after meeting minimum bid By Investing.com - Investing.com India
Market Momentum Report: Hoth Therapeutics Inc (HOTH)’s Negative Close at 1.30 - DWinneX
Hoth Therapeutics Joins 20,000 Biotech Leaders at World's Largest Industry Convention - Stock Titan
Hoth Therapeutics (HOTH) Secures Patent for HT-KIT Platform in J - GuruFocus
Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from D. Boral Capital - Defense World
Hoth Therapeutics secures Japanese patent for mast cell disease treatment By Investing.com - Investing.com South Africa
Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases - MarketScreener
Hoth Therapeutics secures Japanese patent for mast cell disease treatment - Investing.com
Hoth Therapeutics Secures 15-Year Japanese Patent Protection for Revolutionary Mast Cell Disease Platform - Stock Titan
Hoth Therapeutics (HOTH) Receives 'Buy' Rating from D. Boral Capital | HOTH Stock News - GuruFocus
Hoth Therapeutics Inc Stock (HOTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):